Form 4: Aquestive Therapeutics SVP, Chief Financial Officer A. Ernest Toth Jr. Reports Tax Withholding Transaction

A. Ernest Toth Jr., SVP and Chief Financial Officer of Aquestive Therapeutics, Inc., reports the withholding of 11,705 common stock shares to cover tax obligations related to vesting Restricted Stock Units on March 9, 2024.

Summary

• On March 9, 2024, A. Ernest Toth Jr., the SVP and Chief Financial Officer of Aquestive Therapeutics, Inc., had 11,705 shares of common stock withheld by the issuer.
• This withholding was to satisfy the reporting person's tax obligations related to the vesting of previously granted Restricted Stock Units (RSUs).
• The price per share for the transaction was $4.88.
• Following the transaction, Toth directly owns 248,295 shares of Aquestive Therapeutics, Inc.

Sentiment

Score: 5

Explanation: This is a routine transaction related to executive compensation and tax obligations, with no inherent positive or negative implications for the company's overall outlook.

Industry Context

This is a standard Form 4 filing, reflecting a common practice of companies withholding shares to cover employee tax obligations upon the vesting of stock-based compensation.

Stakeholder Impact

• The transaction has a minor impact on the total number of outstanding shares, but is primarily related to internal compensation and tax matters.

Key Dates